deals 
Fierce Pharma
APRIL 7, 2024
Last year closed with a flurry of big-money biopharma deals. Market research by McKinsey found that smaller, strategic M&A deals provide greater shareholder returns than multibillion-dollar acquisitions. Analysts from McKinsey and Project Farma explain why and offer advice on how to optimize deals.
Fierce Pharma
APRIL 4, 2024
As Teva advances its Pivot to Growth strategy under CEO Richard Francis, the company is making good on its pledge to beef up its biosimilar pipeline through outside deals. Teva has unveiled a fresh in-licensing accord with Spain’s mAbxience to chip in on an investigational biosimilar spanning multiple oncology indications.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
APRIL 25, 2024
CEO Pascal Soriot argued the deals were made to build the company’s future. . | After AstraZeneca’s recent acquisitions of various technologies across different therapeutic areas, some investors started to wonder if the British pharma is stretching too thin.
Fierce Pharma
FEBRUARY 28, 2024
On the back of its $350 million deal for two late-stage Idorsia assets, Viatris will continue to be “opportunistic” when it comes to making future business development grabs—especially on the comme | On the back of its $350 million deal for two late-stage Idorsia assets, Viatris will continue to be “opportunistic” when it comes to making future business (..)
Advertiser: ZoomInfo
Close more deals with these winning plays! For the first time, we’re sharing the winning plays that took us from scrappy startup to a publicly traded company. Use our proven data-driven plays to grow your pipeline and crush your revenue targets.
Fierce Pharma
DECEMBER 14, 2023
Pfizer’s $43 billion acquisition of Seagen is in the books, the company said on Thursda | It’s a done deal. Pfizer’s $43 billion acquisition of Seagen is in the books, as it becomes the largest M&A transaction in the biopharma industry since AbbVie snatched up Allergan for $63 billion in 2019.
Fierce Pharma
NOVEMBER 20, 2023
s drug pricing policy, the pharma industry has secured a new government spending deal featuring a higher revenue cap and an innovative drug-friendly rebate mechanism. s drug pricing policy, the pharma industry has secured an improved government spending deal. After blasting the U.K.’s After blasting the U.K.’s
Advertiser: ZoomInfo
More often than not, sales leaders strive to accelerate their deal cycle, but it’s critical to also consider the opportunity cost. The bottom line is that, in B2B sales, speed is useless without control.
Advertiser: ZoomInfo
Less organization, more confusion, and fewer deals closed. However, as a company, sales stack, and database grow, it becomes difficult to uphold structure and governance to keep a CRM up-to-date. The result?
Advertiser: ZoomInfo
Whether it’s a business deal or a personal connection, they are a driving force to solidify a foundation of trust. Enter conversational marketing — the new paradigm to tackling your business deals and converting prospects in minutes. Conversations have always been at the heart of our most authentic relationships.
Expert insights. Personalized for you.
256 
Let's personalize your content